We also used an animal model previously generated by intracranial implantation of glioma NS (WT-IDH1 and mIDH1) derived from our genetically engineered animal model to test therapeutic responses.15 Furthermore, we used human glioma cells derived from patients harboring IDH1R132H, in the context of TP53 and ATRX inactivating mutations, to confirm the results obtained from our animal models. The gene discussed is TP53; the disease is central nervous system cancer.